Search Results

There are 16429 results for: content related to: Systemic treatment of metastatic melanoma: New approaches

  1. You have full text access to this OnlineOpen article
    CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

    Cancer Medicine

    Volume 4, Issue 5, May 2015, Pages: 661–672, Luis H. Camacho

    Version of Record online : 25 JAN 2015, DOI: 10.1002/cam4.371

  2. You have free access to this content
    Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

    Cancer

    Volume 119, Issue 9, 1 May 2013, Pages: 1675–1682, Jeffrey S. Weber, Reinhard Dummer, Veerle de Pril, Celeste Lebbé, F. Stephen Hodi and for the MDX010-20 Investigators

    Version of Record online : 7 FEB 2013, DOI: 10.1002/cncr.27969

  3. You have free access to this content
    Checkpoint blocking antibodies in cancer immunotherapy

    FEBS Letters

    Volume 588, Issue 2, January 21, 2014, Pages: 368–376, Chrisann Kyi and Michael A. Postow

    Version of Record online : 23 OCT 2013, DOI: 10.1016/j.febslet.2013.10.015

  4. You have free access to this content
    Systematic review: colitis associated with anti-CTLA-4 therapy

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 4, August 2015, Pages: 406–417, A. Gupta, K. M. De Felice, E. V. Loftus Jr and S. Khanna

    Version of Record online : 15 JUN 2015, DOI: 10.1111/apt.13281

  5. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 35, Issue 10, October 2015, Pages: 963–976, Ninh M. La-Beck, Gary W. Jean, Cindy Huynh, Saeed K. Alzghari and Devin B. Lowe

    Version of Record online : 24 OCT 2015, DOI: 10.1002/phar.1643

    Corrected by:

    Erratum: Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

    Vol. 35, Issue 12, 1205, Version of Record online: 19 DEC 2015

  6. Immune-Related Adverse Events From Immune Checkpoint Inhibitors

    Clinical Pharmacology & Therapeutics

    Volume 100, Issue 3, September 2016, Pages: 242–251, KA Marrone, W Ying and J Naidoo

    Version of Record online : 29 JUL 2016, DOI: 10.1002/cpt.394

  7. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series

    Internal Medicine Journal

    Volume 45, Issue 10, October 2015, Pages: 1066–1073, T. Lam, M. M. K. Chan, A. N. Sweeting, S. M. C. De Sousa, A. Clements, M. S. Carlino, G. V. Long, K. Tonks, E. Chua, R. F. Kefford and D. R Chipps

    Version of Record online : 1 OCT 2015, DOI: 10.1111/imj.12819

  8. You have free access to this content
    Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4)

    Cancer

    Volume 110, Issue 12, 15 December 2007, Pages: 2614–2627, Steven J. O'Day, Omid Hamid and Walter J. Urba

    Version of Record online : 14 NOV 2007, DOI: 10.1002/cncr.23086

  9. You have full text access to this OnlineOpen article
    Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

    Annals of the New York Academy of Sciences

    Volume 1291, Issue 1, July 2013, Pages: 1–13, Jedd D. Wolchok, F. Stephen Hodi, Jeffrey S. Weber, James P. Allison, Walter J. Urba, Caroline Robert, Steven J. O'Day, Axel Hoos, Rachel Humphrey, David M. Berman, Nils Lonberg and Alan J. Korman

    Version of Record online : 17 JUN 2013, DOI: 10.1111/nyas.12180

  10. You have free access to this content
    Poster

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 13, Issue S2, August 2015, Pages: 20–64,

    Version of Record online : 20 AUG 2015, DOI: 10.1111/ddg.12784

  11. You have free access to this content
    Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 14, Issue 7, July 2016, Pages: 662–681, Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Rotraut Mössner, Selma Ugurel, Lisa Zimmer, Ralf Gutzmer and for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO)

    Version of Record online : 4 JUL 2016, DOI: 10.1111/ddg.13047

  12. Melanoma Treatments: Advances and Mechanisms

    Journal of Cellular Physiology

    Volume 230, Issue 11, November 2015, Pages: 2626–2633, Alexander Marzuka, Laura Huang, Nicholas Theodosakis and Marcus Bosenberg

    Version of Record online : 27 JUL 2015, DOI: 10.1002/jcp.25019

  13. You have free access to this content
    New clinical advances in immunotherapy for the treatment of solid tumours

    Immunology

    Volume 145, Issue 2, June 2015, Pages: 182–201, Valentina A. Zavala and Alexis M. Kalergis

    Version of Record online : 30 MAR 2015, DOI: 10.1111/imm.12459

  14. Melanoma Immunotherapy

    Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine

    Volume 77, Issue 6, November/December 2010, Pages: 620–642, Shanthi Sivendran, Bradley Glodny, Michael Pan, Miriam Merad and Yvonne Saenger

    Version of Record online : 23 NOV 2010, DOI: 10.1002/msj.20215

  15. You have free access to this content
    Inhibitory receptors as targets for cancer immunotherapy

    European Journal of Immunology

    Volume 45, Issue 7, July 2015, Pages: 1892–1905, Meghan E. Turnis, Lawrence P. Andrews and Dario A. A. Vignali

    Version of Record online : 6 JUL 2015, DOI: 10.1002/eji.201344413

  16. You have full text access to this OnlineOpen article
    Ipilimumab and radiation therapy for melanoma brain metastases

    Cancer Medicine

    Volume 2, Issue 6, December 2013, Pages: 899–906, Ann W. Silk, Michael F. Bassetti, Brady T. West, Christina I. Tsien and Christopher D. Lao

    Version of Record online : 10 OCT 2013, DOI: 10.1002/cam4.140

  17. You have full text access to this OnlineOpen article
    Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

    British Journal of Clinical Pharmacology

    Volume 78, Issue 1, July 2014, Pages: 106–117, Yan Feng, Eric Masson, David Dai, Susan M. Parker, David Berman and Amit Roy

    Version of Record online : 20 JUN 2014, DOI: 10.1111/bcp.12323

  18. You have free access to this content
    Society for Melanoma Research 2014 Congress

    Pigment Cell & Melanoma Research

    Volume 27, Issue 6, November 2014, Pages: 1169–1241,

    Version of Record online : 23 OCT 2014, DOI: 10.1111/pcmr.12317

  19. Developing melanoma therapeutics: overview and update

    Wiley Interdisciplinary Reviews: Systems Biology and Medicine

    Volume 5, Issue 3, May/June 2013, Pages: 257–271, John B. Korman and David E. Fisher

    Version of Record online : 13 FEB 2013, DOI: 10.1002/wsbm.1210

  20. Morphomics predicts response to ipilimumab in patients with stage IV melanoma

    Journal of Surgical Oncology

    Volume 112, Issue 4, September 15, 2015, Pages: 333–337, Michael S. Sabel, Jay Lee, Anran Wang, Christopher Lao, Sven Holcombe and Stewart Wang

    Version of Record online : 7 AUG 2015, DOI: 10.1002/jso.24003